Micellar nano-drug, preparation method thereof and application of micelle nano-drug in preparation of anti-tumor drugs and tumor imaging agents

By preparing micellar nanomedicines (FPNPs), the problems of penetration and stability of peptide antitumor drugs in the tumor microenvironment were solved, enabling tumor-targeted delivery and immune activation, significantly inhibiting tumor growth, and providing tumor imaging capabilities.

CN118892452APending Publication Date: 2024-11-05JIANGSU INST OF NUCLEAR MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410982163.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing peptide antitumor drugs have limited penetration ability in the tumor microenvironment, resulting in unsatisfactory pharmacokinetics and rapid degradation, making it difficult to effectively stimulate immune activation.

Method used

Micellar nanomedicines FPNPs were prepared by arylation of thiol-modified PEG, RGD cyclic peptides and antigenic short peptides, combined with thin-film hydration and ultrasound technology, to form stable nanoparticles for tumor-targeted delivery and immune activation.

Benefits of technology

FPNPs are enriched in tumor sites, promote cytoplasmic delivery, significantly delay tumor growth, and when combined with αPD-L1, they can effectively inhibit tumor progression without significant toxicity and can be used for tumor imaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892452A_ABST
    Figure CN118892452A_ABST
Patent Text Reader

Abstract

The invention relates to a micelle nano-drug, a preparation method thereof and application of the micelle nano-drug in preparation of anti-tumor drugs and tumor imaging agents, and the preparation method of the micelle nano-drug comprises the following steps: under the condition that at least one of TCEP, beta-mercaptoethanol and dithiothreitol exists, carrying out ultrasonic dispersion on the micelle nano-drug to obtain the micelle nano-drug. Performing arylation reaction on DFBP and sulfydryl of sulfydryl modified PEG, sulfydryl-containing antigen oligopeptide P5 and sulfydryl of sulfydryl modified RGD cyclic peptide respectively to obtain FPPEG, FPP5 and FPRGD respectively; the micellar nano-drug is prepared from a mixed solution of FPPEG, FPP5 and FPRGD through a film hydration method in combination with ultrasound. The micelle nano-drug disclosed by the invention has tumor targeting property, can be obviously enriched at a tumor part, and can be effectively removed through a liver and gall way; the micelle nano-drug can effectively promote cytoplasm delivery, has an obvious cytotoxic effect, can promote immune danger signal release, stimulate anti-tumor immunity and obviously delay tumor growth, and is good in stability and free of obvious toxic signs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the technical field of preparation of anti-tumor drugs and tumor imaging agents, and in particular, relates to a micellar nanomedicine and a preparation method and application thereof. Background Art

[0002] Cancer immunotherapy is seen as a promising treatment strategy that provides the possibility of using the human immune system to fight malignant tumor cells. However, how to effectively regulate the immune system to fully unleash its anti-tumor potential remains a key challenge for the widespread application of this therapy. Studies have shown that most tumors in clinical practice are "cold" tumors. The microenvironment of such tumors is usually accompanied by low levels of immune cell infiltration and high levels of immunosuppression, which hinders the immune activation process and becomes a bottleneck for immunotherapy.

[0003] Peptide-based immunotherapy has attracted much attention as a promising candidate due to its specificity and versatility. However, peptides are inherently small and often exhibit less than ideal pharmacokinetic and biodistribution characteristics. In addition to tumor-penetrating peptides, peptides are limited in their ability to penetrate deep into the tumor microenvironment, further limiting their ability to induce potent immune activation. Furthermore, most peptides cannot withstand the harsh environment in the body, resulting in rapid degradation and reduced efficacy. Clearly, new strategies are needed to overcome these obstacles to enable innovative research in effective immune activation and anti-tumor immunity.

[0004] In this context, the self-assembled micellar nanomedicine prepared by the present invention can simultaneously promote immune activation and tumor targeting. Combined with radioactive labeling, the in vivo behavior of the nanomedicine can be visualized and tracked, providing an important reference for predicting the efficacy and safety of immune activation. Summary of the invention

[0005] The technical problem to be solved by the present invention is to solve the above-mentioned deficiencies of existing polypeptide anti-tumor drugs, thereby providing a micellar nano drug and a preparation method and application thereof.

[0006] The technical solution adopted by the present invention to solve its technical problem is:

[0007] A method for preparing micellar nanomedicine comprises the following steps:

[0008] In the presence of at least one of TCEP, β-mercaptoethanol, and dithiothreitol, DFBP is subjected to arylation reaction with thiol-modified PEG, antigenic short peptide P5 having a thiol group, and thiol-modified RGD cyclic peptide, respectively, to obtain FPPEG, FPP5, and FPRGD, respectively;

[0009] The mixed solution of FPPEG, FPP5 and FPRGD was prepared by thin film hydration method combined with ultrasound to obtain micellar nanomedicine.

[0010] Preferably, the molecular weight of the thiol-modified polyethylene glycol is 200-1000 Da, preferably 350-500 Da.

[0011] Preferably, the structure of the thiol-modified RGD cyclic peptide is one of the following structures:

[0012]

[0013] Preferably, the antigenic short peptide P5 having a thiol group has the following amino acid sequence: GLCTLVAML.

[0014] Preferably, at least one of DMF, DMSO and dichloromethane is used as solvent for the reaction of DFBP with thiol-modified PEG, antigenic short peptide P5 having thiol groups and thiol-modified RGD cyclic peptide, respectively.

[0015] Preferably, the reaction of DFBP with thiol-modified PEG, antigenic short peptide P5 having thiol groups, and thiol-modified RGD cyclic peptide is respectively adjusted to neutral or weakly alkaline using a buffer, and the buffer is preferably PBS and / or TRIS buffer.

[0016] Preferably, the reaction of DFBP with thiol-modified PEG, antigenic short peptide P5 having thiol, and thiol-modified RGD cyclic peptide is carried out at room temperature under stirring reaction conditions.

[0017] Preferably, FPPEG, FPP5 and FPRGD are dissolved in an organic solvent to obtain a mixed solution of FPPEG, FPP5 and FPRGD, and the organic solvent is at least one of dichloromethane and methanol, preferably a mixed solvent of dichloromethane and methanol.

[0018] Preferably, the mixed solution of FPPEG, FPP5 and FPRGD is rotary evaporated to form a thin film, which is then hydrated by adding water, and then ultrasonicated and allowed to stand to obtain micellar nanodrug FPNPs. The rotary evaporation temperature is 20-60°C, preferably 40°C.

[0019] The present invention also provides a micellar nano drug prepared by the method.

[0020] The present invention also provides an application of the micellar nano drug prepared by the above method in the preparation of anti-tumor drugs and tumor imaging agents.

[0021] The beneficial effects of the present invention are:

[0022] 1) The micellar nanomedicine of the present invention has tumor targeting, can be significantly enriched at the tumor site, and can be effectively cleared through the hepatobiliary pathway;

[0023] 2) The micellar nanodrugs of the present invention can effectively promote cytoplasmic delivery, have obvious cytotoxic effects, promote the release of immune danger signals, stimulate anti-tumor immunity, and significantly delay tumor growth. At the same time, the combined administration of the micellar nanodrugs FPNPs and αPD-L1 of the present invention can effectively achieve the effect of inhibiting tumor progression;

[0024] 3) The micellar nanomedicine of the present invention has good stability and no obvious signs of toxicity;

[0025] 4) The micellar nanomedicine of the present invention can be used for tumor imaging after being radioactively labeled. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The technical solution of the present application is further described below in conjunction with the accompanying drawings and embodiments.

[0027] Figure 1 Mass spectra of FPPEG, FPRGD and FPP5 prepared in Example 1;

[0028] Figure 2 A is the particle size distribution diagram of the micellar nanodrug FPNPs prepared in Example 1 measured by DLS; Figure 2 B is a transmission electron microscope (TEM) image of the micellar nanodrug FPNPs prepared in Example 1; Figure 2 C is the potential diagram of the micellar nanodrug FPNPs prepared in Example 1 measured by DLS; Figure 2 D is a graph showing the particle size variation of the micellar nanomedicine FPNPs prepared in Example 1 in different solutions detected by DLS;

[0029] Figure 3 A and 3B are prepared in Example 4 18 PET imaging of F-FPNPs in 4T1 model mice;

[0030] Figure 4 A is a graph showing the survival rates of FPNPs, FPP5, FPRGD, and FPPEG prepared in Example 1 at different concentrations on inoculated 4T1 cells; Figure 4 B and 4C are the results of FPNPs, FPP5, FPRGD, and FPPEG prepared in Example 1 inducing 4T1 cells to express calreticulin (CRT) and the CRT positive rate results;

[0031] Figure 5A-5B is the growth curve of 4T1 tumor after administration of PBS, FPNPs prepared in Example 1, αPD-L1, and FPNPs (micelle nanodrug prepared in Example 1) + αPD-L1, respectively; Figure 5 C is the tumor dissection image after the treatment (each horizontal row corresponds to a treatment group); Figure 5 D is a graph showing the changes in mouse body weight after administration of PBS, FPNPs prepared in Example 1, αPD-L1, and FPNPs (micelle nanodrug prepared in Example 1) + αPD-L1, respectively. DETAILED DESCRIPTION

[0032] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application may be combined with each other.

[0033] The technical solution of the present application will be described in detail below with reference to the accompanying drawings and in combination with embodiments.

[0034] Example 1

[0035] This embodiment provides a method for preparing micellar nanoparticle drug FPNPs, comprising the following steps:

[0036] Using 2.5 mL DMF as solvent, 0.1 μmol of DFBP (decafluorobiphenyl) was mixed with 0.1 μmol of thiol-modified PEG, thiol-modified RGD cyclic peptide, and antigenic short peptide P5 having a thiol group, and 2.4 μmol of TRIS buffer with a pH of 7.1 and 0.25 μmol of TCEP (tris(2-carboxyethyl)phosphine) were added to the reaction solution. The reaction was stirred at room temperature for 4.5 hours to obtain FPPEG, FPRGD, and FPP5, respectively; the structural formula of the thiol-modified PEG is: The structural formula of the FPPEG is: The structural formula of the thiol-modified RGD cyclic peptide is: The structural formula of the FPRGD is: The amino acid sequence of the antigenic short peptide P5 having a thiol group is: GLCTLVAML, and the structural formula is:

[0037] The structural formula of the FPP5 is:

[0038] The mass spectra of FPPEG, FPRGD and FPP5 are as follows Figure 1As shown, the mass spectrometry test conditions are: mass spectrometry instrument name: WATERS MALDI SYNAPT Q-TOF MS; ion scanning mode is a combination of positive scanning and negative scanning; capillary and cone voltages are 3.5 kV and 30 V respectively; ion source temperature: 100 ° C; desolvation temperature: 400 ° C; collision energy: 6 V.

[0039] FPPEG, FPP5, and FPRGD were dissolved in a mixed solution of dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 4:1) in a molar ratio of 6:3:1, and rotary dried at 40°C for 30 min to obtain a continuous film. An appropriate amount of deionized water was added to make the solution concentration 0.2 mg / mL. After ultrasonication for 15 min, the solution was allowed to stand at room temperature for 2 h to obtain micellar nanodrug FPNPs.

[0040] Example 2

[0041] This embodiment provides a method for preparing micellar nanoparticle drug FPNPs, comprising the following steps:

[0042] Using 2.5 mL DMSO as a solvent, 0.2 μmol of DFBP (decafluorobiphenyl) was mixed with 0.2 μmol of thiol-modified PEG, thiol-modified RGD cyclic peptide, and antigenic short peptide P5 having a thiol group, respectively. At the same time, 4.8 μmol of TRIS buffer with a pH of 7.1 and 0.5 μmol of β-mercaptoethanol were added to the reaction solution, and the reaction was stirred at room temperature for 4.5 hours to obtain FPPEG, FPRGD, and FPP5, respectively. The structural formula of the thiol-modified PEG is: The structural formula of the FPPEG is: The structural formula of the thiol-modified RGD cyclic peptide is:

[0043] The structural formula of the FPRGD is:

[0044] The amino acid sequence of the antigenic short peptide P5 having a thiol group is: GLCTLVAML, and the structural formula is:

[0045] The structural formula of the FPP5 is:

[0046] FPPEG, FPP5, and FPRGD were dissolved in a mixed solution of dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 4:1) in a molar ratio of 6:3:1, and rotary evaporated and dried at 20°C for 30 min to obtain a continuous film. An appropriate amount of deionized water was added to make the solution concentration 0.2 mg / mL. After ultrasonication for 15 min, the solution was allowed to stand at room temperature for 2 h to obtain micellar nanodrug FPNPs.

[0047] Example 3

[0048] This embodiment provides a method for preparing micellar nanoparticle drug FPNPs, comprising the following steps:

[0049] Using 2.5 mL of dichloromethane as a solvent, 0.15 μmol of DFBP (decafluorobiphenyl) was mixed with 0.15 μmol of thiol-modified PEG, thiol-modified RGD cyclic peptide, and antigenic short peptide P5 having a thiol group, respectively. At the same time, 3.6 μmol of TRIS buffer with a pH of 7.1 and 0.375 μmol of dithiothreitol were added to the reaction solution, and the reaction was stirred at room temperature for 4.5 hours to obtain FPPEG, FPRGD, and FPP5, respectively. The structural formula of the thiol-modified PEG is:

[0050] The structural formula of the FPPEG is: The structural formula of the thiol-modified RGD cyclic peptide is: The structural formula of the FPRGD is:

[0051] The amino acid sequence of the antigenic short peptide P5 having a thiol group is GLCTLVAML, and the structural formula is:

[0052] The structural formula of the FPP5 is:

[0053] FPPEG, FPP5, and FPRGD were dissolved in a mixed solution of dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 4:1) in a molar ratio of 6:3:1, and dried by rotary evaporation at 60°C for 30 min to obtain a continuous film. An appropriate amount of deionized water was added to make the solution concentration 0.2 mg / mL. After ultrasonication for 15 min, the solution was allowed to stand at room temperature for 2 h to obtain micellar nanodrug FPNPs.

[0054] Example 4 FPNPs 18 F radiolabeling

[0055] 18 F was obtained on a PET cyclotron. 18 F]F - The solution was loaded into a syringe and pushed into the QMA column. 1 mL of a mixed solution of TBAHCO3 and anhydrous acetonitrile (volume ratio of 1:1) was taken and the [ 18 F]F - Wash off and get TBA 18 F solution, and then 1 mL of TBA 18F was heated with 1.5 mL of anhydrous acetonitrile at 105°C to remove water by azeotropic reaction, and this was repeated three times until it was completely blown dry to obtain an anhydrous reaction mixture. Then, 0.3 μmol of FPPEG was added, and DMSO was used as the reaction liquid. The fluoride ion exchange reaction was carried out at room temperature for 15 minutes. After the reaction, it was mixed with 10 times the volume of deionized water and pushed into a Sep-Pak C-18 column. The Sep-Pak C-18 column was eluted with deionized water two to four times until the radioactivity remained basically unchanged to remove free [ 18 F]F - . Take 0.3mL of ethanol and pass it through the column. 18 F-FPPEG was released from the cartridge.

[0056] Will 18 F-FPPEG, FPP5 and FPRGD were dissolved in a mixed solution of dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 4:1) at a molar ratio of 6:3:1, and dried by rotary evaporation at 40°C for 30 min to obtain a continuous film. An appropriate amount of deionized water was added to make the solution concentration 0.2 mg / mL. After ultrasonication for 15 min, the solution was allowed to stand at room temperature for 2 h to allow nanomicelles to form. 18 F-FPNPs.

[0057] Effect Example 1 Determination of FPNPs Particle Size

[0058] Take 1 mL of the prepared FPNPs nanoparticle solution and transfer it to a dynamic light scattering (DLS) measuring dish. Use DLS to measure its particle size. The parameters are set to: 25 ° C, equilibrium time is 10 s, and the measurement is repeated three times. The final result is the average of the three measurement results. The results show that the average hydrated diameter of the nanoparticles is about 150 nanometers. The test results of the FPNPs nanoparticles prepared in Example 1 are as follows: Figure 2 As shown in A.

[0059] Effect Example 2 Transmission electron microscopy (TEM) observation of the morphology of nanomedicine FPNPs

[0060] The prepared FPNPs solution was mixed with deionized water to a concentration of 0.1 mg / mL, and 2 μL of the mixed solution was dropped onto a copper grid. The morphology of the FPNPs was examined on a Tecnai G2-20 instrument operated at 200 kV to obtain a transmission electron microscope (TEM) image. Results: The nanoparticles were spherical in shape, with uniform particle size and an average particle size of about 150 nm. The test results of the FPNPs nanoparticles prepared in Example 1 are shown in FIG. Figure 2 As shown in B.

[0061] Effect Example 3 Determination of FPNPs Potential

[0062] Take 1 mL of the FPNPs nanoparticle solution prepared in Example 1, transfer it to a cuvette, and use dynamic light scattering (DLS) to measure its potential. The parameters are set as follows: 25°C, equilibrium time is 10s, and the measurement is repeated three times. The final result is the average of the three measurement results. The results are as follows: Figure 2 As shown in C, the Zeta potential of the nanoparticles is -33.4 mV.

[0063] Effect Example 4 Study on the Stability of FPNPs Nanoparticles

[0064] In order to study the in vitro stability of FPNPs nanoparticle solution, a certain amount of the nanoparticle solution prepared in Example 1 was mixed with an equal amount of physiological saline and a mixture of physiological saline and serum (volume ratio of 9:1) and incubated at 4°C. After 0, 24, 48 and 72 hours, 1 mL of the mixed solution was taken, and the particle size was measured in DLS to evaluate the in vitro stability of the nanodrug. The measurements were repeated three times. The results are shown in Figure 2 As shown in D (FBS in the figure represents a mixed solution of FPNPs nanoparticle solution miscible with a mixture of physiological saline and serum), within 72 hours, the particle size of FPNPs did not change significantly, proving that the nanoparticles have good stability in vitro.

[0065] Effect Example 5 18 PET imaging of F-FPNPs in 4T1 model mice

[0066] Will 18 F-FPNPs were injected into 4T1 tumor model mice through the tail vein, with 100 μCi injected into each mouse. PET images of the experimental subjects were collected at different times (0.5, 1, 2, 3 h) after intravenous injection under isoflurane anesthesia, and each acquisition lasted for 10 minutes. The obtained Micro PET raw data were reconstructed with the help of the three-dimensional ordered subset expectation maximization algorithm (3D-Ordered Subset Expectation Maximization, OSEM3D), and the reconstructed image data were deeply analyzed using ASIPro professional image analysis software. For each experimental mouse, the researchers accurately defined the region of interest (ROI) of major organs and tissues including tumors, heart, liver, etc. on the image by manually outlining. Further, by quantitatively calculating the radioactive uptake intensity of each ROI, a quantitative indicator using the percentage of injected dose per gram of tissue (% Injected Dose per gram, % ID / g) as the measurement standard was obtained. The results are shown in the figure below. Figure 3 As shown, the probe is significantly enriched in the tumor site and can be effectively cleared through the hepatobiliary pathway.

[0067] Effect Example 6 In vitro pharmacodynamic study of FPNPs

[0068] After inoculating 4T1 cells, different concentrations of FPNPs, FPP5, FPRGD, and FPPEG (2, 4, 6, 8, 10, 12, and 14 μM) in Example 1 were used to replace the culture medium and incubated for 24 hours. 10 μL of CCK-8 solution was added to each well, and the culture plate was placed in an incubator for 2 hours. The absorbance at 450 nm was measured with an ELISA instrument, and the ratio between the absorbance OD value of the drug group and the absorbance OD value of the blank control group reflected the survival rate of the drug on the cells. The results are shown in FIG. Figure 4 As shown in A, FPNPs effectively promoted cytosolic delivery and amplified the cytotoxic effect.

[0069] 4T1 cells were incubated with cell culture medium solutions containing FPNPs, FPP5, FPRGD, and FPPEG (14 μM) in Example 1 for 24 h, incubated with rabbit anti-CRT antibody at 4°C for 30 min, and then stained with CoraLite488 at 4°C for 30 min. The expression of CRT on the cell surface was analyzed by flow cytometry. The results are as follows: Figure 4 As shown in BC, FPNPs have a strong ability to induce ICD and release tumor-associated antigens, which may activate CD8 + T cell-related anti-tumor immune response, FPNPs can increase the positive rate of CRT to 23%, that is, FPNPs can effectively promote the release of immune danger signals and stimulate anti-tumor immunity.

[0070] Effect Example 7 In vivo pharmacodynamic study of FPNPs

[0071] 4T1 tumor model mice were constructed. When the average tumor volume reached 150mm 3 Treatment was started at about 1:00 p.m., and tumor-bearing mice were injected with PBS, FPNPs, αPD-L1, and FPNPs+αPD-L1, respectively. The treatment was once every two days for a total of four times. PBS and FPNPs were injected into the tail vein at a dose of 10 mg / kg each; αPD-L1 was injected intraperitoneally at a dose of 3 mg / kg. The dosage and method of FPNPs and αPD-L1 in combined treatment were consistent with those of single drugs. The in vivo efficacy of nanomedicines was evaluated by monitoring tumor growth. The results are shown in Figure 5 As shown in AC, monotherapy with FPNPs or αPD-L1 significantly delayed tumor growth compared with the control group. At the same time, the combined administration of FPNPs and αPD-L1 increased the synergistic inhibition of tumor progression by 2.3 and 2.0 times (average of tumor volume in each treatment group on the last day) compared with the use of FPNPs or αPD-L1 alone, respectively. No obvious signs of toxicity or weight loss were observed in all treatment groups, such as Figure 5 As shown in D.

[0072] Based on the above ideal embodiments of this application, the relevant staff can make various changes and modifications without departing from the technical concept of this application through the above description. The technical scope of this application is not limited to the content in the specification, and its technical scope must be determined according to the scope of the claims.

Claims

1. A method for preparing micellar nanomedicine, characterized in that: The method comprises the following steps: in the presence of at least one of TCEP, β-mercaptoethanol and dithiothreitol, DFBP is subjected to arylation reaction with thiol-modified PEG, antigen short peptide P5 having thiol, and thiol of thiol-modified RGD cyclic peptide, respectively, to obtain FPPEG, FPP5, and FPRGD, respectively; The mixed solution of FPPEG, FPP5 and FPRGD was prepared by thin film hydration method combined with ultrasound to obtain micellar nanomedicine.

2. The method for preparing micellar nanomedicine according to claim 1, characterized in that: The molecular weight of the thiol-modified polyethylene glycol is 200-1000 Da, preferably 350-500 Da.

3. The method for preparing the micellar nano drug according to claim 1 or 2, characterized in that: The structure of the thiol-modified RGD cyclic peptide is one of the following structures:

4. The method for preparing the micellar nano drug according to any one of claims 1 to 3, characterized in that: The antigenic short peptide P5 having a thiol group has the following amino acid sequence: GLCTLVAML.

5. The method for preparing the micellar nano drug according to any one of claims 1 to 4, characterized in that: The reactions of DFBP with thiol-modified PEG, antigenic short peptide P5 having thiol groups, and thiol-modified RGD cyclic peptide, respectively, use at least one of DMF, DMSO, and dichloromethane as solvent; the reactions of DFBP with thiol-modified PEG, antigenic short peptide P5 having thiol groups, and thiol-modified RGD cyclic peptide, respectively, preferably use a buffer to adjust the reaction solution to neutral or weak alkalinity, and the buffer is preferably PBS and / or TRIS buffer.

6. The method for preparing the micellar nano drug according to any one of claims 1 to 5, characterized in that: The reactions of DFBP with thiol-modified PEG, antigenic short peptide P5 having thiol groups, and thiol-modified RGD cyclic peptide were carried out at room temperature under stirring reaction conditions.

7. The method for preparing the micellar nano drug according to any one of claims 1 to 6, characterized in that: FPPEG, FPP5 and FPRGD are dissolved in an organic solvent to obtain a mixed solution of FPPEG, FPP5 and FPRGD. The organic solvent is at least one of dichloromethane and methanol, preferably a mixed solvent of dichloromethane and methanol.

8. The method for preparing the micellar nano drug according to any one of claims 1 to 7, characterized in that: The mixed solution of FPPEG, FPP5 and FPRGD is rotary evaporated to form a thin film, which is then hydrated by adding water, and then ultrasonicated and allowed to stand to obtain micellar nanodrug FPNPs. The rotary evaporation temperature is 20-60°C, preferably 40°C.

9. A micellar nanomedicine prepared by the method according to any one of claims 1 to 8.

10. Use of the micellar nanomedicine according to claim 9 in the preparation of anti-tumor drugs and tumor imaging agents.